Maravai LifeSciences Holdings, Inc. (MRVI)

From the record

Maravai LifeSciences Holdings, Inc.'s filings since 2020 show 3 warning events of 3 kinds: a warning not to rely on past financial statements (8-K item 4.02, the latest 2025-03-18); an auditor change (8-K item 4.01, the latest 2025-07-18); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-03-04) (its current reports).

From the record

Maravai LifeSciences Holdings, Inc.'s 7 filed years say what it did: revenue went from $143 million in fiscal 2019 to $186 million in fiscal 2025, up 4.4% a year; it rose in 3 of 6 years; the deepest fall was 79% from fiscal 2022 to fiscal 2025; net income was positive in 3 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Maravai LifeSciences Holdings, Inc.'s diluted share count shrank about 17.3% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales (2 under scheduled 10b5-1 plans) and 3 purchases of their own stock on the open market in the year to 2026-11-12, buying about $1 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Maravai LifeSciences Holdings, Inc. lost about 35 cents for every dollar of shareholders' money, and gross profitability: its products earned about 4 cents per dollar of everything the company owns. Leverage: it owed about 52 cents per dollar of assets, and net share issuance: its share count grew 4.7% over the year (the filed statements).

From the record

Maravai LifeSciences Holdings, Inc.'s standing among 315 graded names in its industry family: revenue of $186 million in fiscal 2025 ranks in the top 29% by size; a net margin of -70.4% ranks in the top 42%; revenue growth of -40.5% a year over the last 3 filed years ranks in the bottom 12% (its annual reports).

From the record

Maravai LifeSciences Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Brust, Bernd (Chief Executive Officer, as filed), filing under that title since 2025-06-10, 1.4 years (bottom 19% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 6 years (top 42%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 24%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Maravai LifeSciences Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $217 million against debt of $292 million leaves -9.7% of its assets as net cash, bottom 10% of its family; cash from operations less capital spending is -38.1% of revenue (top 43%); a gross margin of 18.3% (bottom 9%); research spending of 9.4% of revenue (bottom 14%) (its annual report).

From the record

Maravai LifeSciences Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -40.5% a year over the last three filed years against 4.4% over all 7, slowing (bottom 14% of its family); the newest year grew -28.4% (bottom 25%); research spending grew -1.8% a year (bottom 44%); capital spending grew -8.4% a year (top 46%) (its annual reports). Maravai LifeSciences Holdings, Inc. reported 2 lines of business in fiscal 2025: Tri Link at $120 million (65%), Cygnus at $66 million (36%); 1 of 2 grew against the year before (its annual report).

From the record

Maravai LifeSciences Holdings, Inc.'s newest year against its own record: revenue of $186 million in fiscal 2025 came in 32.2% above the $140 million its prior three years' pace pointed to (top 23% of its family); net income of $131 million against a prior three-year average of $15 million (bottom 3%); a net margin of -70.4% against -24% before (bottom 23%) (its annual reports).